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(57) ABSTRACT 
The present invention provides a method for detecting or 
screening for the presence of cancer in a Subject. The method 
comprises obtaining, providing or collecting a tissue or fluid 
sample (Such as a urine sample) from said subject, and then 
determining the presence or absence of delta-catenin in said 
sample, or increased levels of delta-catenin in said sample as 
compared to a normal or control Subject. The presence of 
delta-catentin in said sample, or increased levels of delta 
catenin in said sample, indicating said Subject is afflicted with 
or at least at risk of developing cancer. 
5 Claims, 9 Drawing Sheets 
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1. 
METHOD OF DETECTING CANCERUSING 
DELTA-CATENIN 
RELATED APPLICATIONS 
This application claims the benefit of U.S. Provisional 
Patent Application Ser. No. 60/483,666, filed Jun. 30, 2003, 
the disclosure of which is incorporated by reference herein in 
its entirety. 
BACKGROUND OF THE INVENTION 
Prostate cancer is a major cause of death among men in 
Western countries. The current protocol for detection of this 
cancer involves testing for prostate-specific antigen (PSA) 
levels. If PSA levels are found to be high (4 ng/ml), a tissue 
biopsy is performed. Unfortunately, PSA testing is limited by 
the fact that it lacks sensitivity and it does not distinguish 
between prostate cancer and benign prostate hyperplasia. As 
a result, many men either are not identified as having the 
disease or because of false positive tests are subjected to the 
invasive tissue biopsies when they do not have the disease. A 
much more specific andless invasive diagnostic test is needed 
for early detection of this disease. 
Delta-catenin presents itself as an improved alternative to 
the PSA/biopsy tests currently utilized for prostate cancer 
detection. Delta catenin was first identified and patented (U.S. 
Pat. No. 6,258,929) as a neurospecific protein, alternatively 
named ALARM. At the time, the protein was believed to be 
expressed almost exclusively in brain tissue. However, 
Burger, et al. (Int. J. Cancer 100, 228-237 (2002)) subse 
quently found the messenger RNA for delta-catenin to be 
expressed in prostate cancer tumors with the delta-catenin 
transcripts being localized to the glandular secretory cells. 
Unlike PSA, delta-catenin was capable of distinguishing 
between prostate cancer and benign prostate hyperplasia. 
Burger et al. noted a possible diagnostic role for delta-catenin 
in prostate cancer detection. However, they also pointed out 
that a significant difficulty remained in development of this 
tool since delta-catenin had only been detected in glandular 
secretory epithelial cells in prostate tissues and had not been 
found in prostate stroma or bodily fluids, such as serum or 
U1. 
SUMMARY OF THE INVENTION 
The present invention shows that delta-catenin mRNA and 
protein are expressed not only in prostate cancer tissues but 
also in many other cancer types. For example, in esophageal 
cancer, delta-catenin expression, like in prostate cancer, 
increases with the increasing tumor grade. Thus, its useful 
ness may extend beyond detection of prostate cancer. More 
over, it has now been found that when over-expressed, delta 
catenin can be detected not only in the affected epithelial 
tissues but also in the extracellular spaces and stroma. As a 
result, the invention has overcome the barrier in using delta 
catenin as a specific, non-invasive diagnostic tool for prostate 
and other types of cancer. 
Thus the present invention provides a method for detecting 
or screening for the presence of cancerina Subject. In general, 
the method comprises obtaining, providing or collecting a 
tissue or fluid sample (such as a urine sample) from said 
Subject, and then determining the presence or absence of 
delta-catenin in said sample, or increased levels of delta 
catenin in said sample as compared to a normal or control 













increased levels of delta-ctanin in said sample, indicating said 
subject is afflicted with or at least at risk of developing cancer. 
A further aspect of the present invention is a method as 
described above, wherein the presence of at least one addi 
tional cancer biomarker Such as a cadherin, prostate specific 
antigen, and/or p120 in the subject is also detected. The 
presence of at least one additional biomarker indicates the 
subject is more likely afflicted with cancer; the absence of at 
least one additional biomarker indicates the Subject is less 
likely afflicted with cancer. The use of multiple biomarkers, at 
least one of which is delta-cadherin as described herein, 
serves to reduce the number of false positives and false nega 
tives detected by any one biomarker alone, particularly where 
the other biomarker is a cadherin such as E-cadherin or p120. 
A further aspect of the present invention is the use of an 
anti-delta-catenin antibody for carrying out a method as 
described above. 
Another aspect of the present invention is the use of a 
nucleic acid amplification technique Such as the polymerase 
chain rection (PCR), particularly reverse transcriptase-poly 
merase chain reaction (RT-PCR) with delta-catenin specific 
primers for carrying out a method as described above. 
The foregoing and other objects and aspects of the present 
invention are explained in greater detail in the drawings 
herein and the specification set forth below. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Expression of delta-catenin protein in cancer and 
its association with cancer progression. 
FIG. 1a. Ah schematic drawing illustrating the full length 
structure of the delta-catenin protein, consisting of 1247 
amino acids. MAbD30, UB1, RAb64, RAb08, and RAb07 
are epitopes to which antibodies have been made. No clear 
significance in protein function by these epitopes is known, 
but it is believed that rab64 contains the armadillo domain 
that may be involved in protein-protein interaction; rab08 
contains several protein phosphorylation sites that may be 
important for signal transduction; rab08 also contains a PDZ 
binding motif that directs binding to PDZ proteins. PDZ 
proteins are a diverse group of Scaffolding proteins that are 
important to bring proteins together for function. 
FIG. 1b. Expression of delta-catenin in prostate cancer 
(CaP). 40 ug of proteins were loaded in each lane. Lane 1 is 
the D30 epitope, lane 2 is the UBI epitope, etc.). 
FIG. 2. Western blot demonstrating differential expression 
of delta-catenin in various tissues as compared to an actin 
control. 
FIG. 2A and FIG. 2B. Each lane was loaded with 40 ug 
protein from four different types of tissue culture cells. Lane 
1, cortical neurons; Lane2, PZ-HPV-7 non-cancerous human 
prostate cells: Lane 3, HS-5 human bone marrow stromal 
cells: Lane 4, CWR-R1 human prostate tumor cells. FIG. 2A 
was immunoblotted with anti-delta catenin antibodies. FIG. 
2B was immunoblotted with anti-actin antibodies. 
FIG. 2C and FIG. 2D. Each lane was loaded with 80 ug of 
protein from either CWR22 xenograft tumors (Lanes 1-3) or 
mouse brain tissue (Lane 4). Lane 1, tissue taken at initial 
tumor formation; Lane 2, 2 days post-castration; Lane 3, 150 
days post-castration; Lane 4, mouse brain tissue. Molecular 
weight is indicated on the left. FIG. 2C was immunoblotted 
with anti-delta catenin antibodies and FIG. 2D was immuno 
blotted with anti-actin antibodies. (Note that castration will 
reduce androgen level in the body and cause the tumor to 
shrink; delta-catenin expression is down 2 days after castra 
tion, which coincided with tumor shrinkage and cell apopto 
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sis/cell death, but was back up after 150 days post-castration, 
a condition called tumor recurrence that is androgen indepen 
dent). 
FIG. 3. A transmission electron micrograph showing 
excretion of delta-catenin into extracellular spaces by cells in 
which the protein is being over-expressed. Arrows indicate 
the structures reacting with delta-catenin antibody. 
FIG. 4. Evidence of promotion of cell invasion by delta 
catenin. 
FIG. 4a. Fluorescent light microscope photographs of 
prostate tumor cells. Panels A and B: prostate tumor cells that 
have well differentiated morphology show strong staining for 
p120ctn (A), but not delta-catenin; Panels C and D: prostate 
tumor cells that show more motile phenotype display strong 
delta-catenin staining, but a reduced p120ctn staining; Insert: 
higher magnification showing high expression of delta 
catenina S clusters in D. 
FIG. 4b. A graphic presentation of the percent cell of inva 
sion promoted by delta-catenin as compared to a control. 
Lamin B dsRNA, delta-catenin dsRNA, delta-catenin cDNA. 
A BD Bioscience MATRIGELTM Invasion Chamber assay 
was used. The chamber assay apparatus consists of two cham 
bers. The upper chamber has a cursion of matrix protein 
called Matrigel and has cells plated on top of that. Invasive 
cells will be able to penetrate the gel and migrate to the lower 
chamber. More cells on the lower side of the chamber indi 
cates higher potential for invasion. 
FIG. 5. Delta-catenin expression in prostate, breast, ova 
rian, pancreatic, colon, adrenal cancer and leukemia cells. 
Different cancer types were probed with delta-catenin anti 
body or an actin antibody control. Lane 1, endothelial cells; 
Lane 2, HS-5, human bone marrow stromal cell line; Lane 3 
PZ-HPV-7, normal human prostate epithelial cells; Lane 4, 
CWR-R1, prostate cancer cell line; Lane 5, MCF-7, breast 
cancer cells, Lane 6, Jurkat, human leukemia T cell line, Lane 
7, Ovarian cancer cells; Lane 8, Panc-1, human pancreatic 
cancer cell line; Lane 9, HT-29, human colon adenocarci 
noma cells; Lane 10, PC12-8-cat, pheochromocytoma cells 
(adrenal cancer) (8-cat=transformed with delta-catenin). This 
particular figure shows the transformed PC12 cells, in which 
delta-catenin band is used as positive control for delta-cate 
nin). 
FIG. 6. Tissue Microarray showing a high percentage of 
prostate cancer cases with upregulated delta-catenin expres 
Sion. The samples come from commercial source of prostate 
cancertissues, are well characterized prostate cancer Samples 
(meaning that the tumor grade and Gleason scores are known, 
and are immunostained with anti-delta-catenin). 
FIG. 7. Delta-catenin overexpression in the extracellular 
spaces of prostate cancer tissue. Arrows point to glandular 
secretory epithelial cells, whereas arrowheads point to extra 
cellular matrix and stroma). 
FIG. 7A. Normal prostate tissue shows glandular structure 
without delta-catenin immunoreactivity. 
FIG. 7B. Stage 1 tumor shows glandular structure with 
minimal delta-catenin immunoreactivity. 
FIG. 7C. Stage 2 tumor shows enhanced delta-catenin 
immunoreactivity in the secretory epithelial cells of the gland 
without extracellular staining. 
FIG. 7D. Stage 4 tumor shows strong delta-catenin immu 
noreactivity in the extracellular space. 
FIG.8. Ö-Catenin overexpression in primary human pros 
tatic adenocarcinomas. 
FIG. 8A. Semi-quantitative immunoscore showing low 
immunoreactivity of Ö-catenin (meants.e. of immun 
oscore 2.52+0.04) in benign samples and high immunoreac 














prostatic adenocarcinomas. An immunoscore was obtained 
as: extent score X intensity score (range, 0 to 12). 
FIG. 8B. Semi-quantitative immunoscore showing 
increases in mean immunoscore with prognostically 
increased Gleason score. The immunoscore was obtained 
similarly as in A. 
FIG.9. Increased 8-catenin immunoreactivity is accompa 
nied by the reduced E-cadherin and p120' immunostaining 
during prostate cancer progression. A and B. Correlation 
between the changes in the intensity (A) and extent (B) of 
Ö-catenin immunoreactivity and the Gleason scored prostatic 
adenocarcinomas. C and D. Correlation between the changes 
in the intensity (C) and extent (D) of E-cadherin immunore 
activity and the Gleason scored prostatic adenocarcinomas. E 
and F. Correlation between the changes in the intensity (E) 
and extent (F) of p120" immunoreactivity and the Gleason 
scored prostatic adenocarcinomas. Asterisks: p-0.05 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The present invention is explained in greater detail below. 
This description is not intended to be a detailed catalog of all 
the different ways in which the invention may be imple 
mented, or all the features that may be added to the instant 
invention. For example, features illustrated with respect to 
one embodiment may be incorporated into other embodi 
ments, and features illustrated with respect to a particular 
embodiment may be deleted from that embodiment. In addi 
tion, numerous variations and additions to the various 
embodiments suggested herein will be apparent to those 
skilled in the artin light of the instant disclosure which do not 
depart from the instant invention. Hence, the following speci 
fication is intended to illustrate some particular embodiments 
of the invention, and not to exhaustively specify all permuta 
tions, combinations and variations thereof. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
belongs. The terminology used in the description of the inven 
tion herein is for the purpose of describing particular embodi 
ments only and is not intended to be limiting of the invention. 
“Cancer as used here includes but is not limited to brain, 
lung, breast, colon, prostate, esophageal, ovarian, pancreatic, 
adrenal, skin cancer and leukemia cells. 
“Subject' as used herein refers to animal subjects, particu 
larly mammalian Subjects, including but not limited to, 
humans, non-human primates, dogs, cats, rabbits, goats, 
horses, pigs, and cattle. The Subject may be a male Subject or 
a female Subject and may be of all ages including infant, 
juvenile, adolescent and adult Subject. 
“Fluid sample' or “body fluid sample” as used herein 
includes but is not limited to blood samples, seminal fluid, 
urine, and fine needle aspirates from Suspected afflicted 
organs such as the prostate in a Subject. 
“Blood sample as used here refers to whole blood, blood 
plasma, blood serum or any fraction thereof. So long as the 
fraction contains (in Subject with cancer) delta-catenin as 
described herein. 
Antibody” as used herein refers to intact immunoglobulin 
molecules having binding affinity to delta-catenin, as well as 
immunologically active fragments thereof. Such as Fab., Fab'. 
F(ab')2, etc. Antibodies include any type of immunoglobulin 
and may be monoclonal, polyclonal or chimeric and may be 
of any species of origin, including (for example) mouse, rat, 
rabbit, horse, or human. See, e.g., M. Walker et al. Molec. 
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Immunol. 26, 403-11 (1989), may be substituted or unsubsti 
tuted, and may be naturally occurring or synthetic. 
The disclosures of all U.S. patent references cited herein 
are to be incorporated by reference herein in their entirety. 
The present invention is, as noted above, drawn to methods 
for detection of cancer utilizing delta-catenin. Detection may 
be for diagnostic or prognostic purposes, may be for general 
screening purposes, may be for targeting cancer in chemo 
therapy, or may be for the purpose of determining if a subject 
is at risk of developing cancer, confirm a diagnosis, indicate 
the reoccurence of cancer, etc. 
One aspect of the invention is drawn to obtaining a fluid 
sample from a subject and determining the presence or 
absence of delta-catenin in said fluid sample; the presence of 
delta-catenin indicating that said Subject is afflicted with or at 
least at risk for developing cancer. In one preferred embodi 
ment, the fluid sample is a blood sample. 
As noted above, the Subject may be a human Subject, oran 
animal Subject for veterinary or drug screening or develop 
ment purposes, with examples of Suitable animal Subjects 
including but not limited to to dogs, cats, rabbits, goats, 
horses, pigs, cattle, etc. The Subjects may be a male Subject or 
a female Subject; the Subject may be of any age including 
including infant, juvenile, adolescent and adult Subjects. 
The present invention may be used to detect any type of 
cancer, including but not limited to esophageal, lung, breast, 
colon, ovarian, pancreatic, adrenal, skin cancer or leukemia. 
In one preferred embodiment of the invention, the cancer to 
be detected is prostate cancer. 
As noted above, the present invention provides a method of 
screening for the presence of cancer in a subject, comprising 
the steps of: (a) contacting a biological sample taken from 
said subject with an antibody or delta-catenin specific primers 
as described above under conditions permitting said antibody 
or primers to specifically bind an antigen or delta-catenin 
nucleic acid sequences in the sample to form an antibody 
antigen complex or PCR reaction complex; and then (b) 
determining the amount of antibody-antigen complex or 
delta-catenin RNA in the sample as a measure of the amount 
of antigen or RNA in the sample, wherein an elevated level of 
the antigen or RNA in the sample is associated with the 
presence of cancer in said Subject. Other techniques for deter 
mining the quantity of delta-catenin in a Subject or sample 
taken from a subject that do not involve antibodies and immu 
noassays or RT-PCR can also be used (e.g., chromatography 
techniques), but antibody and RT-PCR assay techniques are 
currently preferred. 
The delta-catenin (also called ALARM) protein and anti 
bodies thereto are known. See, e.g., U.S. Pat. No. 6,258,929 to 
Kosiketal; Q. Lu et al., J. Neurosci Res. 67,618 (2002), and 
antibodies for carrying out the present invention can be pro 
duced in accordance with known techniques. For example, 
monoclonal antibodies of the present invention may be pre 
pared using any technique which provides for the production 
of antibody molecules by continuous cell lines in culture. 
These include, but are not limited to, the hybridoma tech 
nique, the human B-cell hybridoma technique, and the EBV 
hybridoma technique (Kohler, G. et al. (1975) Nature 256: 
495-497; Kozbor, D. etal. (1985).J. Immunol. Methods 81:31 
42; Cote, R. J. et al. (1983) Proc. Natl. Acad. Sci. 80:2026 
2030; Cole, S. P. et al. (1984) Mol. Cell Biol. 62:109-120). 
Briefly, the procedure is as follows: an animal is immunized 
with antigen or immunogenic fragments or conjugates 
thereof. For example, haptenic oligopeptides of antigen can 
be conjugated to a carrier protein to be used as an immunogen. 
Lymphoid cells (e.g. splenic lymphocytes) are then obtained 













cells (e.g. myeloma or heteromyeloma) to produce hybrid 
cells. The hybrid cells are screened to identify those which 
produce the desired antibody. Polyclonal antibodies used to 
carry out the present invention may be produced by immu 
nizing a suitable animal (e.g., rabbit, goat, etc.) with the 
delta-catenin antigen, collecting immune serum from the ani 
mal, and separating the polyclonal antibodies from the 
immune serum, in accordance with known procedures. 
Depending on the host species, various adjuvants may be used 
to increase immunological response. Such adjuvants include, 
but are not limited to, Freunds, mineral gels such as alumi 
num hydroxide, and Surface active Substances such as lyso 
lecithin, pluronic polyols, polyanions, peptides, oil emul 
sions, keyhole limpet hemocyanin, and dinitrophenol. 
Among adjuvants used in humans, BCG (bacilli Calmette 
Guerin) and Corynebacterium parvum are especially prefer 
able. 
The step of determining the delta-catenin content of the 
fluid sample (for example, urine) may comprise contacting 
the urine sample with anti-delta catenin antibodies and mea 
Suring the amount of the anti-delta catenin-antigen complex, 
wherein elevated levels of antigen-antibody complex indi 
cates the presence of cancer. Any suitable assay format can be 
used, a variety of which will be known to persons skilled in 
the art. 
Those skilled in the art will be familiar with numerous 
specific immunoassay formats and variations thereof which 
may be useful for carrying out the method disclosed herein. 
See generally E. Maggio, Enzyme-Immunoassay, 
(1980)(CRC Press, Inc., Boca Raton, Fla.); see also U.S. Pat. 
No. 4,727,022 to Skold etal. titled “Methods for Modulating 
Ligand-Receptor Interactions and their Application.” U.S. 
Pat. No. 4,659,678 to Forrest et al. titled “Immunoassay of 
Antigens.” U.S. Pat. No. 4,376,110 to David et al., titled 
“Immunometric Assays. Using Monoclonal Antibodies. U.S. 
Pat. No. 4,275,149 to Litman et al., titled “Macromolecular 
Environment Control in Specific Receptor Assays.” U.S. Pat. 
No. 4,233,402 to Maggio et al., titled “Reagents and Method 
Employing Channeling,” and U.S. Pat. No. 4,230,767 to 
Boguslaski et al., titled “Heterogenous Specific Binding 
Assay Employing a Coenzyme as Label.” 
Antibodies as described herein may be coupled or conju 
gated to a solid Support Suitable for a diagnostic assay (e.g., 
beads, plates, slides or wells formed from materials such as 
latex or polystyrene) in accordance with known techniques, 
Such as precipitation. Antibodies as described herein may 
likewise be conjugated to detectable groups such as radiola 
bels (e.g., S., I, ''I), enzyme labels (e.g., horseradish 
peroxidase, alkaline phosphatase), fluorescent labels (e.g., 
fluorescein), chemiluminescent labels (e.g., acridinium 
groups, metalloporphyrins such as phthalocyanine dyes, 
luminol, etc.), metal atoms (e.g., technetium-99m), etc., in 
accordance with known techniques. See, e.g., U.S. Pat. No. 
4,472,509 to Gansow (metal chelates to monoclonal antibod 
ies); U.S. Pat. No. 5,061,641 to Schochat et al.; and U.S. Pat. 
No. 4,861,869 to Nicoleotti et al. (radiolabelling proteins). 
Amplification of nucleic acids may be carried out by any 
Suitable technique, including but not limited to polymerase 
chain reaction (including, for RNA amplification, reverse 
transcriptase polymerase chain reaction), ligase chain reac 
tion, strand displacement amplification, transcription-based 
amplification (see D. Kwoh et al., Proc. Natl. Acad. Sci. USA 
86, 1173-1177 (1989)), self-sustained sequence replication 
(or "3SR) (see J. Guatelli et al., Proc. Natl. Acad. Sci. USA 
87, 1874-1878 (1990)), the Q.beta. replicase system (see P. 
Lizardi et al., Biotechnology 6, 1197–1202 (1988)), nucleic 
acid sequence-based amplification (or “NASBA) (see R. 
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Lewis, Genetic Engineering News 12 (9), 1 (1992)), the repair 
chain reaction (or “RCR) (see R. Lewis, supra), and boo 
merang DNA amplification (or “BDA) (see R. Lewis, 
Supra). The bases incorporated into the amplification product 
may be natural or modified bases (modified before or after 
amplification), and the bases may be selected to optimize 
Subsequent electrochemical detection steps. Techniques for 
amplification are known and described in, among other 
things, U.S. Pat. Nos. 4,683, 195; 4,683.202; 4,800,159; and 
4,965, 188: G. Walker et al., Proc. Natl. Acad. Sci. USA 89, 
392–396 (1992); G. Walker et al., Nucleic Acids Res. 20, 
1691-1696 (1992); R. Weiss, Science 254, 1292 (1991). 
Immunoassays, or other types of assays to detect and/or 
quantitate the level of delta-catenin in samples as described 
below, may be used in Screening assays to detect pathologic 
states associated with aberrant levels of delta-catenin expres 
sion (e.g., tumors, inflammatory states), diagnostic studies, 
prognostic Studies, or to monitor the progression or diminu 
tion of delta-catenin expression in correlation with disease 
State. 
Samples that may be collected for use in carrying out the 
immunoassay or nucleic acid assay may be blood samples or 
tissue samples from the organ or tissue of interest within the 
Subject, Such tissue generally of most interest being those 
types of tissues/cells that express differing amounts of delta 
catenin in pathologic States as compared to non-pathologic 
states, or biological fluids such as blood (including blood 
fractions such as blood plasma or blood serum), urine, cere 
broSpinal fluid, etc). Examples may include overexpression 
or aberrant expression of delta-catenin in various types of 
malignancies as described herein, 
A biological sample may be a cell sample, with an inter 
vening culturing step being performed between the time the 
cell sample is collected from the Subject and the immunoas 
say is carried out on the biological sample. 
A biological sample may also be a cell, cell debris, or 
stroma sample, with an intervening step being performed 
before the sample is collected from the subject to enhance the 
sensitivities of immunoassay. 
For immunohistological techniques, a tissue sample is col 
lected from the subject, and the presence or absence of bind 
ing of an antibody of the invention is detected. The presence 
of binding of the antibody in an abnormal pattern or a pattern 
indicative of a tumor or cancer indicates the presence of a 
tumor or cancer in the Subject from which the tissue sample is 
collected. The presence of the antigen in a metastatic tumor 
deposit can also be used to determine a likely source of the 
primary tumor. Any Suitable immunohistology format may be 
used. The tissue sample may include patient biopsies, resec 
tions or cells for cytologic study. A similar technique to 
immumohistogy is the use of similar techniques to detect 
and/or phenotype cells in body fluids or other Suspensions as 
is used for flow cytometric examination. 
For in Vivo diagnostic purposes the antibody according to 
the invention is coupled to or provided with a suitable exter 
nally detectable label, such as e.g. a radiolabel as described 
above or a metal atom (e.g., technetium-99m), and adminis 
tered to a Subject (e.g., by intraveneous or intraarterial injec 
tion), in an amount Sufficient to produce an externally detect 
able signal, whereupon the possible localized accumulation 
of antibody in the body is determined, with a localized accu 
mulation of the antibody (in a region other than that which 
would ordinarily be expected for normal subjects or subjects 
free of disease) indicating the present of a tumor in that 
Subject. 
Anti-delta-catnin antibodies can be packaged in any Suit 













ods described herein and provided as a kit for carrying out the 
methods described herein, in accordance with known tech 
niques. 
Another aspect of the invention involves the use of a com 
bination of biomarkers to reduce the frequency of false posi 
tives or false negatives by the use of any one biomarker alone. 
For example, where a subject is tested for 6-catenin in the 
manner described herein, that subject may also be tested for 
the presence of another biomarker. For example, the presence 
of at least two biomarkers indicates that the subject is more 
likely to be afflicted with cancer than if only one biomarker is 
found in that subject; the absence of at least two biomarkers 
indicates the subject is more likely to be free of cancer than if 
only one biomarker is found in that subject; the presence of 
one biomarker in a subject indicates the Subject is more likely 
to be afflicted with cancer than if the subject is found to be free 
of another, different, biomarker, etc. Particular biomarkers 
that may be used in combination with the methods of testing 
for 6-catenin as described herein include tight junction and 
adherens junction proteins such as claudin and cadherin (par 
ticularly E-cadherin), prostate specific antigen, and p120 
(particularly p120°"). 
The presence or absence of other cancer biomarkers may 
be detected in accordance with known techniques. Methods 
of detecting, diagnosing or screening for cancer (particularly 
prostate cancer) by detecting the presence of prostate specific 
antigen (PSA) are known and described in, among other 
things, U.S. Pat. Nos. 5.614,372; 5,840,501; 6,300,088; 
6,361,955; 6,383,759; 6,423,503; and 6,482,599. Methods of 
detecting, diagnosing or screening for cancer (including pros 
tate cancer) by detecting cadherins such as E-, OB-, N- and 
T-cadherin (particularly E-cadherin) are known and 
described in, among other things, U.S. Pat. Nos. 5,597.725: 
5,811,518; 5,997,866; 6,682,901; and 6,723,320. Methods of 
detecting, diagnosing or screening for cancer by detecting 
p120 (includingp120") are known and described in, among 
other things, U.S. Pat. No. 4.902,615. The disclosures of all 
patent references cited herein are to be incorporated by ref 
erence herein in their entirety. 
The present invention is illustrated in greater detail in the 
following non-limiting Examples. 
Experimental 
Antibodies specific for delta-catenin were developed using 
standard techniques known in the art. 
FIG. 1a identifies the specific epitopes of the delta-catenin 
protein to which the antibodies were made. Expression of 
delta-catenin in prostate cancer cells is shown in FIG. 1b with 
the each of antibodies reacting with the prostate cancer cells. 
FIG. 2A further demonstrates the differential expression of 
delta-catenin where the antibodies are shown to react specifi 
cally with cancerous prostate cells (lane 4) and not with 
non-cancerous prostate cells (lane 2) or bone marrow stromal 
cells. Additionally, as was previously known, the delta-cate 
nin is expressed in brain tissues (FIG. 2A, lane 1 and FIG. 2C, 
lane 4). FIGS. 2B and 2D serve as positive controls of con 
stitutive levels of expression and also as a control to demon 
strate a constant level of protein loading. The expression of 
delta-catenin in the cancerous but not in the non-cancerous 
prostate cells demonstrates the potential improvement of this 
protein as a method of detecting prostate cancer over the 
commonly used, less sensitive PSA test. 
FIG. 6 shows upregulation of delta-catenin in a high per 
centage of prostate cancer cases. The tissue array has many 
prostate cancer needle biopsy samples spotted onto slides and 
immunostained with anti-delta-catenin. Among these pros 
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tate cancer samples each case was identified with certain 
tumor grade and Gleason score to indicate the tumor stage 
from early, more differentiated tumore tissues to late, poorly 
differentiated tumor tissue that may also be very invasive. 
Delta-catenin overexpression was seen in many of these 
samples and the higher the tumor grade it is, the stronger the 
staining. 
This invention further demonstrates the expression of 
delta-cateinin in a wide variety of cancer types in addition to 
prostate cancer (FIG. 5). Lanes 4-10 of FIG. 5A show delta 
catenin expression in prostate, breast, ovarian, pancreatic, 
colon, adrenal cancer and leukemia cells. Delta-catenin anti 
body did not react with endothelial cells or bone marrow 
stromal cells demonstrating its differential expression in only 
specific tissue types (Lanes 1 and 2). FIG. 5B is an actin 
antibody control to Verify a constant level of protein loading. 
Low levels of delta-catenin were detected in prostate non 
cancerous cells. So it is the level of protein rather than its 
presence or absence that is of greatest importance. In general, 
the level of delta-catenin in normal tissue is very low, except 
for brain; In this case, the cell line PZ-HPV-7 is a non 
cancerous cells, but to make it immortal and can grow in 
culture, it is trinasformed with HPV). The tissue IHC, though, 
shows clearly that delta-catenin staining in normal prostate 
tissue is extremely low. 
This invention for the first time demonstrates delta-catenin 
expression in extracellular spaces (FIG.3 and 7). The trans 
mission electron micrograph (FIG. 3) of cells overexpresss 
ing delta-catenin. shows extracellular structures that are 
immunoreactive with delta-catenin antibody. The progres 
sion of expression of delta-catenin expression in different 
stage prostate tumors is shown in FIG. 7. Normal prostate 
glandular tissue showed no immunoreactivity with delta 
catenin antibodies (FIG. 7A). Stage 1 and stage 2 prostate 
tumor tissues (FIGS. 7B and 7C) showed minimal to 
enhanced intracellular levels of delta-catenin immunoreac 
tivity, respectively, while stage 4 tumor tissue (FIG. 7D) 
showed strong delta-catenin immunoreactivity in the extra 
cellular spaces. Extracellular expression of delta-catenin is an 
important aspect in the development of delta-catenin as a 
non-invasive test for prostate cancer because it will allow the 
sampling of bodily fluids and not just tissues. 
Experimental 2 
Materials. Mouse anti-E-cadherin, mouse anti-pp120 and 
mouse anti-Ö-catenin D30 (to amino acids 85-194) were from 
BD Biosciences (Palo Alto, Calif.). Affinity purified rabbit 
anti-human Ö-catenin was developed as previously described 
(Lu, Q.,et al., JCell Biol. 144(3): 519-532, 1999; Ho, C. et al., 
J Comp Neurol. 420 (2): 261-276, 2000). They were raised 
againstamino acids 434-530 (raB62), amino acids 828-1022 
(rab64), and amino acids 1213-1225 (rab25). Mouse anti 
actin was from Oncogene Science (Boston, Mass.). Unless 
otherwise indicated, all chemicals were from Sigma (St. 
Louis, Mo.). 
Cell culture and cDNA transfection. PC12 cells were 
grown in DMEM with 10% heat inactivated horse serum and 
5% fetal bovine serum (FBS). Human endothelial cell lysates 
were obtained from BD Biosciences (Palo Alto, Calif.). Non 
tumorigenic prostate epithelial PZ-HPV-7 (ATCC, Rockville, 
Md.) was cultured in serum-free karotinocyte medium, while 
tumorigenic prostate cancer CWR-R1 was cultured in Rich 
ter's improved minimal essential medium (Invitrogen, Carls 
bad, Calif.) supplemented with epidermal growth factor 
(EGF), insulin/transferin/selenium, nicotinamide, linoleic 













277(43): 40449-40455, 2002). Primary hippocampal cultures 
were prepared as described by Goslin and Banker (1998) with 
minor modifications (Lu, Q. et al., J Cell Biol. 144(3): 519 
532, 1999; Jones, S. B. et al., Neuroscience 115 (4): 1009 
1021, 2002). Briefly, 18-day timed pregnant rats were sacri 
ficed, and the embryos were removed in accordance with the 
NIH Guide for the Care and Use of Laboratory Animals. 
Hippocampi and cortices were collected, and cells were dis 
Sociated by trypsinization and plated onto poly-L-lysine 
coated coverslips and cell culture plates, respectively. After 
neurons adhered to the Substrate, the medium was changed 
over to B-27 supplemented Neurobasal. All cultures were 
maintained at 37° C. with 5% CO, until they were either fixed 
or lysed for immunochemical analysis. 
Some cells were transfected with 6-catenin cDNA to evalu 
ate the effects of 6-catenin overexpression on p120' expres 
sion and distribution. For neuronal cultures, hippocampal 
neurons grown for 5 days in vitro (DIV) were transfected with 
pEGFP (Clontech, Palo Alto, Calif.) as control, or with 
pEGFP-8-catenin using Lipofectamine 2000 reagent (Life 
Technologies Grand Island, N.Y.) according to instructions 
provided. Transfection of PZ-HPV-7 and CWR-R1 cells were 
performed with using Lipofectinamine-Plus method. 
Protein extraction and immunoblotting. Cultured cells 
were lysed in a radioimmunoprecipitation assay (RIPA) 
buffer containing 10 mM HEPES, pH 7.3, 150 mM NaCl, 2 
mM EDTA, 1% TritonX-100, 0.5% deoxycholate, 0.2% SDS 
with protease inhibitor cocktails. Insoluble materials were 
removed by centrifugation. For human benign and prostate 
tumor tissues, cell lysates were prepared from the frozen 
peripheral Zones of prostatic acinar tissues by extraction in 
150 mMNaCl, 50 mM Tris, pH 7.5, with 0.5% NP-40% with 
1 mM sodium vanadate, 1 mM Na Fluoride, 1 mM PMSF, 10 
ug/ml leupeptin, 10 ug/ml pepstatin, and 10 ug/ml aprotinin. 
The lysates were mixed with sample buffer and equal protein 
amounts were loaded for SDS-PAGE analysis. After proteins 
were transferred to nitrocellulose membranes (PGCScientif 
ics, Frederick, Md.), anti-Ö-catenin (1:500 for rabbit antibod 
ies and 1:300 for mouse antibodies) and anti-actin (1:5000) 
immunoreactivities were revealed by antibody immunoblot 
ting using enhanced chemiluminescence (Amersham Life 
Science, Piscataway, N.J.) for detection. When necessary, 
blots were stripped with 100 mM f-mercaptoethanol, 2% 
SDS, and 62.5 mM Tris-HCl, pH 7.6 for 30 minutes at 55° C. 
The blots were then washed in Tris buffer containing 0.1% 
Tween 20 before reprobing with different antibodies. 
RNA isolation and RT-PCR. The total RNA was isolated by 
guanidinium thiocyanate-phenol-chloroform extraction 
(Jeansonne, B. et al., Cell Mol Biol. 49 (1): 13-21, 2003). To 
synthesize the first-strand DNA sequence from the total RNA, 
random decamers were used as a first-strand primer (Ambion 
Inc., Austin, Tex.). The specific PCR primers chosen to yield 
the 283 bp fragment of 6-catenin are as follows: forward 
(5'-3"), TACTCCGCAAGACGACTGACC, and reverse (5'- 
3'), CCATCACACTCTCTCATCCTTCTG. The annealing 
temperature in the PCR reaction is 56° C. Some of the RT 
PCR products were purified from the DNA geland verified by 
the DNA sequencing to confirm the 6-catenin sequence. 
Tissue MicroArray Specimens. The Tissue MicroArray 
(TMA) block was constructed from archival paraffin blocks 
of radical prostatectomy (RP) cases performed at Vanderbilt 
University Medical Center from January 1998 to December 
2001. RP specimens were submitted in their entirety for 
whole mount processing. Total tumor Volume by digital 
planimetry, Gleason score, tumor stage, and status of surgical 
margins were assessed as described (Brooks, J. D. Microarray 
analysis in prostate cancer research. Curr Opin Urol. 12 (5): 
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395-399, 2002). Ninety cases were retrieved from a main 
tained RP Pathology database to achieve the following grade 
and stage combinations: 15 Gleason score 5 or 6, pT2: 15 
Gleason score 5 or 6, pT3; 15 Gleason score 7, pT2: 15 
Gleason score 7, pT3; 15 Gleason scorele8, pT2: 15 Gleason 
scorele8, pT3 (Chung, C. H. et al., Nat Genet. 32 Suppl. 
533-540 (2002); Feroze-Merzoug, F. et al., Cancer Metasta 
sis Rev. 20 (3-4): 165-171 (2001)). Portions of tumor repre 
sentative of the case were identified by review of tumor maps 
and individual whole mount slides. Representative areas of 
tumor and benign (typically peripheral Zone), corresponding 
to the Zone of origin of the prostate cancer in the vast majority 
of cases (Brooks, Supra), were identified on whole mount 
slides and matched to the corresponding paraffin blocks. The 
TMA block was constructed with a Beecher Instruments Tis 
Sue Array (Silver Spring, Md.) utilizing two representative 
0.6 mm areas of tumorandone 0.6 mm area of benign percase 
(total of 270 samples). 
Immunohistochemistry. For immunohistochemistry, 5um 
sections were cut from the TMA block onto charged glass 
slides. The TMA slides were subjected to antigen retrieval for 
all antibodies. After deparaffination and rehydration, tissue 
sections were placed in a pressure cooker on high for 15 
minutes in Trilogy retrieval solution (Cell Marque, Hot 
Springs, Ark.). Sections were then immunostained with rab 
bit anti-Ö-catenin, mouse anti-E-cadherin or anti-p120" 
using Dako Autostainer with the LSAB 2 protocol (labeled 
streptavidin-biotin method, Dako Corp., Carpenteria, Calif.). 
The streptavidin-biotin reaction was detected using diamion 
obenzidine as a Substrate. All sections were counterstained 
with Hematoxilin and coversliped using a Sakura TissueTek 
(Sakura Corp, Torrance, Calif.). TMA immunostaining was 
assessed in benign and tumor samples in a blinded manner for 
both extent and intensity of immunoreactivity. Extent of 
immunostaining on one section was defined as the epithelial 
area that showed positive 6-catenin immunoreactivity and 
was scored semi-quantitatively as follows: 0, absent: 1+. 
<25%; 2+, 25-50%; 3+, 51-75%; 4+, >75%. Intensity of 
immunostaining was scored semi-quantitatively as follows: 
0, negative: 1+, weak; 2+, moderate; 3+, strong. 
Two pathologists from two different groups assigned Glea 
son scores for the TMA independently. When the TMA slides 
were studied for 6-catenin immunoreactivity, one analysis 
was performed with the aid of automated digital reading and 
an immunoscore was obtained as: extent score X intensity 
score (range, 0 to 12). In another analysis, manual reading 
was applied, and the immunoscores for the staining intensity 
and staining extent were assigned separately. For tumors with 
both samples (two representative 0.6 mm areas as described 
above) present, the immunoscore was the mean of the two 
scores for the separately assessed samples. They were ana 
lyzed semi-quantitatively by light microscopy equipped with 
MetaMorph imaging Software (Universal Imaging Corp. 
West Chester, Pa.). 
Data and Statistical Analyses. To examine the relationship 
among 8-catenin, E-cadherin and p120', the serial sections 
were photographed and the distribution and expression of 
these proteins were analyzed. Statistical analysis was per 
formed using MS Excel and SigmaPlot 5.0 (SPSS Science, 
Chicago, Ill.). Student t-tests were conducted and p-value was 
assigned. The significance level was set at 0.05. 
Results 
8-Catenin is overexpressed in prostate cancer cells. Previ 
ous studies indicated that 8-catenin mRNA is expressed in 
tumor cell lines (Lu et al., supra 1999; Lu, Q. et al., JNeurosci 
Res. 67 (5): 618-624, 2002), and is overexpressed in prostate 














(Burger, M.J. et al., IntJ Cancer 100(2): 228-237, 2002). To 
determine ifö-catenin protein expression is increased in pros 
tate cancer cells, we first compared human marrow stromal 
cells HS-5 and non-cancerous human prostate epithelial cells 
PZ-HPV-7 with CWR-R1, a cell line derived from a recurrent 
CWR22 human prostate tumor xenograft (Pretlow, T. G. et 
al., JNatl Cancer Inst. 85 (5): 394–398, 1993: Wainstein, M. 
A. et al., Cancer Res. 54 (23): 6049-6052, 1994: Nagabhus 
han, M. et al., Cancer Res. 56 (13): 3042-3046, 1996; Gre 
gory, C. W. et al., Cancer Res.61(7): 2892-2898, 20010). 
Although Western Blots showed that 8-catenin is expressed in 
all of the cell lines, its expression in CWR-R1 cells is signifi 
cantly higher than in HS-5 and PZ-HPV-7 cells (data not 
shown). Ö-Catenin immunoreactivity is authentic since it co 
migrates with 6-catenin in cortical neurons (data not shown), 
where 8-catenin expression has been well established (Lu et 
al., 1999; Lu et al., 2002; Jones, S. B. et al., Neuroscience 115 
(4): 1009-1021, 2002). Ö-Catenin expression in CWR-R1 
cells has also been confirmed by the use of four independent 
6-catenin antibodies: mAbD30, which recognizes amino 
acids 85-194; rab62, which recognizes amino acid residues 
434-530; rab64, raised against amino acid residues 828 
1022; and rab25, an antibody that recognizes amino acid 
residues 1201-1225 (data not shown). To determine if the 
enhanced level of 6-catenin protein in cancer cells detected by 
Western Blot might be due to an increased mRNA expression 
of 6-catenin gene, we applied RT-PCR and found that CWR 
R1 cells displayed increased amounts of 8-catenin mRNA 
when compared with PZ-HPV-7 cells (data not shown). These 
results demonstrated that Ö-catenin protein is overexpressed 
in prostate cancer cells in vitro. In addition, an enhanced 
mRNA expression is at least partially responsible for the 
overexpression of Ö-catenin. 
Ö-Catenin expression is increased in human prostatic 
adenocarcinomas. In the only study to previously examine 
changes in Ö-catenin expression in cancerous tissues, Burger 
et al (Id) compared 6-catenin mRNA expression using real 
time PCR in 16 prostate tumor and 11 BPH tissue samples. 
These investigators reported that levels of 6-catenin mRNA 
expression in all tumor samples examined were higher than in 
any of the BPH samples. However, no correlation between 
Ö-catenin mRNA expression and tumor progression was 
observed (Id.). To extend this study of the association 
between 6-catenin expression and the progression of human 
prostate cancer, an immunohistochemical analysis of the 
Ö-catenin protein expression in human prostatic adenocarci 
nomas was conducted using Tissue MicroArray (TMA). 
We have performed immunohistochemistry on TMA 
samples that contained 90 cases of prostatic adenocarcinomas 
and 90 benign prostatic tissue samples (data not shown). Two 
pathologists from two groups independently assigned Glea 
son scores to the tumor specimens. One pathologist deter 
mined the Gleason scores without prior knowledge of patient 
information. In one analysis, an immunoscore was obtained 
as: extent score X intensity score (range, 0 to 12, see Material 
and Method). An estimated 85% of the prostate cancer speci 
mens showed enhanced immunoreactivity when compared to 
the benign prostatic tissue samples from the peripheral Zones 
of the glands (Table I). The meants.e. of the immunoscore for 
benign samples was 2.52+0.04. For tumor samples, the mean 
its.e. of the immunoscore was 7.58+0.05 (FIG. 8A). In 65 of 
90 cases, both benign and tumors can be compared and 
assessed. The immunoscore was increased in tumor versus 
benign in 55 of 65 cases (or 85%); whereas the immunoscore 
of cancer and benign samples was equal in 6 out of 65 (or 9%) 
cases, and the immunoscore was higher in benign versus 
tumor in only 4 out of 65 (or 6%) cases (Table I). The mean 
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tumor scores appeared to increase with prognostically signifi 
cant increased Gleason scores. In this analysis, we observed 
an immunoscore of 6.24 in the tumors with Gleason score 5,6; 
an immunoscore of 7.69 in the tumors with Gleason score 7: 
an immunoscore of 8.75 in tumors with Gleason scoree8 
(FIG. 8B). 
In an independent experiment in which protein lysates 
from 8 cases of high-grade prostate tumors were compared to 
8 cases of benign prostate tissues sampled from the peripheral 
Zone of the glands, Ö-catenin showed an increased immunore 
activity in 5 cases or ~63% of all specimens (data not shown). 
Semi-quantitative analysis showed that Ö-catenin immunore 
activity in prostate cancer lysates increased approximately 
80% when compared to that in benign samples. 
When prostate gland images were analyzed, anti-Ö-catenin 
immunostaining was very weak in benign tissues (data not 
shown). In the prostatic adenocarcinomas with low tumor 
grade, 6-catenin staining was localized to the secretory glan 
dular epithelial cells (data not shown). The number of 6-cate 
nin-positive cells expanded in prostate cancer samples with 
high tumor grade (data not shown). 
These results together demonstrated that Ö-catenin expres 
sion is increased in primary human prostatic adenocarcino 
aS. 
Increased expression of 6-catenin is associated with the 
downregulation of E-cadherin and p120' in human prostatic 
adenocarcinomas. In the second analysis in which consecu 
tive sections were immunostained with anti-Ö-catenin, anti 
E-cadherin and anti-p120", extent score and intensity score 
were determined separately to see if the results might be 
different from that obtained in the first analysis described 
above. Here, 92% of the prostate cancer samples showed 
strong (46 out of 72 cases) or moderate (20 out of 72 cases) 
staining (immunoscore equal or above 2) for 6-catenin, only 
6 out of 72 (or 8%) of the specimens was either negative or 
with immunoscore below 2 (Table II, Cancer). Interestingly, 
while 49 out of 65 cases (or 75%) of benign specimens 
showed an immunoscore of below 2, 6 out of 65 (or 9%) of 
benign samples showed an immunoscore equal to 2, and 10 
out of 65 (or 15%) of benign specimens showed an immun 
oscore above 2. This data indicates that a small percentage of 
cases will be falsely judged positive for prostate cancer if 
benign specimens are evaluated using 6-catenin immun 
oscore as the sole criteria. 
When anti-E-cadherin immunoreactivity was analyzed, 
96% of benign specimens showed strong (64 out of 71 cases) 
or moderate (4 out of 71 cases) staining (immunoscores equal 
or greater than 2), only 3 out of 71 cases (or 4%) of the benign 
specimens showed an weak immunoreactivity (less than 2), 
indicating an excellent correlation between strong E-cadherin 
expression and benign prostate tissues (Table II). However, 
anti-E-cadherin immunoreactivity was strong (39 out of 89 
cases) or moderate (20 out 89 cases) in 66% of the prostate 
cancer cases, with only 30 out of 89 cases (or 34%) showed an 
immunoscore lower than 2. These observations showed that 
relying on E-cadherin immunoreactivity alone could have 
very high probability of missing prostate tumors, especially 
in the low Gleason score tumors. It should be noted that these 
data were derived from the average of total prostate cancer 
cases. In the most aggressive cases of prostatic adenocarci 
nomas (Gleason scored8), over 71% (or 10 out of 14 cases) of 
the specimens showed a sharply reduced immunoscores 
below 2, consistent with the literature that E-cadherin is down 
regulated in the more advanced prostatic adenocarcinomas. 
In benign specimens, anti-p120" showed an overwhelm 
ingly strong immunoreactivity of above immunoscore 2 (71 













of the prostatic adenocarcinomas retained fairly strong anti 
p120' immunoreactivity of above 2, with only 21% of the 
cases showing immunoscore below 2 (Table II). This indi 
cates that additional biomarkers is necessary to compensate 
for p120' for detecting prostate cancer, particularly in the 
low Gleason score tumors. Similar to anti-E-cadherin immu 
nostaining, anti-p120" staining was dramatically reduced in 
the more aggressive cases of prostatic adenocarcinomas 
(Gleason scores 8), consistent with the notion that both 
E-cadherin and p120” are tumor suppressors. 
Using 8-catenin, E-cadherin and p120" as biomarker 
cluster improves the probability of predicting or excluding 
prostate cancer. We further analyzed the data set to determine 
whether E-cadherin and p120' immunoreactivity can be 
used to correct the false negative results associated with the 
8% of the prostate cancer cases that showed weak anti-8- 
catenin immunoreactivity. Our hypothesis was that from 
these 6 cases where 6-catenin immunoscore was weak, per 
haps the 6-catenin epitopes were not preserved appropriately 
during tissue processing, or 6-catenin level in Some patients 
was inherently low. If this was the case, employing anti-E- 
cadherin or anti-p120" may circumvent the problem of mis 
diagnosis. Indeed, in these 6 cases that showed weak 8-cate 
nin immunoreactivity, anti-E-cadherin staining of the 
consecutive sections was able to correctly predict prostate 
cancer in 4 cases (or 67%), while anti-p120' immunoreac 
tivity can compensate for 83% of the time (or 5 out of 6 
cases)(Table III). The probability to correct these 6 false 
negative cases stands at 83% when both data from anti-E- 
cadherin and anti-p120' staining were used (Table IV). This 
would result in only 1 case out of total 72 prostatic adenocar 
cinomas (or 1.4%) that showed a false negative in predicting 
prostate cancer when examining 6-catenin, E-cadherin and 
p120" as a biomarker cluster. 
As shown above, anti-E-cadherin and anti-p120' showed 
strong immunostaining in both benign and the majority of 
prostatic adenocarcinomas, particularly in the low Gleason 
score specimens. Therefore, although the down regulation of 
these two proteins was closely associated with the high Glea 
son score prostatic adenocarcinomas, it would not be safe to 
rely on these markers to predict early stage prostate cancer. 
Table II showed that, in 39 out of 89 (or 44%) of the prostate 
cancer specimens, E-cadherin immunoreactivity remained 
strong. When these 39 cases were evaluated for anti-8-catenin 
and anti-p120' staining, 24 out of 39 cases (or 62%) showed 
strong immunoreactvity for 6-catenin and 5 out of 39 cases 
(or 13%) showed reduced immunostaining of p120' (Table 
III). Because the correction by 8-catenin and p120" immu 
noreactivity happened in the overlapping cases, there was a 
total 62% of chances that these prostate cancer cases will be 
discovered if all three biomarkers were used in predicting 
prostatic adenocarcinomas (Table IV). In prostate cancer 
specimens, 62 out of 88 (or 70%) of the specimens showed 
strong anti-p120' immunoreactivity, while only 18 out of 88 
(or 21%) of the cases displayed a clearly reduced anti-p120" 
staining intensity (Table II). The majority of these 18% cases 
came from the high Gleason score prostatic adenocarcino 
mas. When anti-Ö-catenin immunoreactivity in these 62 cases 
was analyzed, 31 cases (or 58%) showed enhanced immun 
oscores, whereas 29 out of 62 cases (or 47%) showed reduced 
E-cadherin signal, consistent with the presence of prostatic 
adenocarcinomas in these cases (Table III). Therefore, here 
the combination of anti-Ö-catenin and E-cadherin immun 
ostaining can correctly detect 49 out of 62 (or 79%) prostate 
cancer cases that otherwise would be judged falsely negative 
using anti-p120" immunostaining as the only criteria (Table 
IV). 
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Similarly, using 8-catenin, E-cadherin and p120" as 
biomarker cluster can reduce false positive outcomes and 
increase the probability in excluding prostate cancer misdi 
agnosis in benign populations. For example, 7 cases of benign 
tissues showed moderate or reduced anti-E-cadherin immu 
noreactivity (Table II). Anti-Ö-catenin immunoreactivity was 
able to correct 4 out of 7 cases (or 57%). 10 cases (or 15%) of 
benign tissues showed strong anti-Ö-catenin immunoreactiv 
ity, while 6 cases (or 9%) of benign samples showed moderate 
anti-Ö-catenin immunoreactivity. This result Suggested that 
16 out of 65 benign cases might be misinterpreted as having 
prostate cancer. When these cases were examined using anti 
E-cadherin as a marker, 13 of them (or 81%) showed strong 
immunoreactivity. Although all benign specimens (71/71 or 
100%) showed strong anti-p120" immunoreactivity (Table 
II), p120" immunoreactivity is also strong in many cases of 
early stage prostatic adenocarcinomas. Therefore, relying on 
p120" immunoreactivity alone may lead to false negative 
results. Since most of the prostate cancer cases that showed 
falsely strong E-cadherin and p120" staining did not show 
the same falsely weak 8-catenin staining (Table III and Table 
IV), the non-overlapping nature of the false positive and false 
negative cases suggest that it is possible to exclude many of 
the false positive outcomes if these three biomarkers are used 
for analysis. 
Increased 6-catenin expression is associated with the down 
regulation of E-cadherin and p120" during the progression 
of prostatic adenocarcinomas. Interestingly, Ö-catenin immu 
noreactivity increased significantly in high-grade prostate 
intraepithelial neoplasia (PIN), the most likely pre-invasive 
stage of prostatic adenocarcinomas. With increasing Gleason 
score, 6-catenin immunoreactivity continued to increase the 
intensity and extent until the prostatic adneocarcinoma reach 
Gleason score 10. At this stage, while the extent of 8-catenin 
staining remained the same, the intensity off-catenin staining 
decreased somewhat (FIGS. 9A and B). The E-cadherin and 
p120" immunoreactivities, on the other hand, showed a 
reciprocal trend in expression when compared with 6-catenin 
immunoreactivity (FIG. 9C-F). E-cadherin expression 
decreased significantly in PIN, but remained at the same level 
as in PIN in the tumors with Gleason scores 6 and 8. Then in 
Gleason 10 tumors, E-cadherin immunoreactivity reduced 
dramatically, reflecting the dispersion and the invasiveness of 
the tumor cells. The intensity of p120" expression did not go 
down significantly in PIN and Gleason 6 tumors. Even in the 
Gleason 8 tumors, the intensity and the extent of p120" 
immunoreactivity remained quite strong. However, in the 
Gleason 10 tumors, both the intensity and extent of p120" 
immunoreactivity reduced sharply (FIGS. 9E and F). 
Increased 6-catenin expression is accompanied by the 
redistribution of E-cadherin and p120" in the same tumor 
clusters of prostatic adenocarcinomas. One advantage of ana 
lyzing the serial sections of a single case is that all three 
cell-cell junction biomarkers in the same tumor cell clusters 
can be compared. In benign prostate glandular epithelial 
cells, 8-catenin immunoreactivity was quite weak (data not 
shown). Anti-E-cadherin immunoreactivities were strong and 
were concentrated at the cell-cell contact area, consistent with 
its localization to the adherens junction (data not shown). 
There was very little anti-E-cadherin immunoreactivity in the 
cytoplasm. Similarly, p120' immunoreactivity was clearly 
localized at the cell-cell junction (data not shown). In the 
low-grade prostatic adenocarcinomas (Gleason score 6), 
Ö-catenin immunoreactivity was generally increased, and can 
be more evident in some cells than others in the same tumor 
clusters (data not shown). In some of these tumor clusters, the 













E-cadherin and p120" can be directly compared. For 
example, 6-catenin immunoreactivity was junctional in the 
central part of the tumor cluster. However, in the peripheral 
cell layer of the tumor cluster, not only the intensity of 6-cate 
nin immunoreactivity was higher, but also most of the signal 
became non-junctional. When E-cadherin and p120" immu 
noreactivity were analyzed in the same tumor clusters, they 
showed strongjunctional staining corresponding to the center 
of the cluster (data not shown), but became more cytoplasmic 
at the periphery of the tumor cluster (not shown). Neverthe 
less, the intensity and the extent of anti-E-cadherin and anti 
p120" immunostaining did not reduce significantly in many 
of the low-grade prostatic adenocarcinomas. In the prostatic 
adenocarcinomas with high Gleason score of 10, cell-cell 
junctions were severely disrupted. Here, anti-Ö-catenin 
immunoreactivity showed intense cytoplasmic staining (not 
shown). Most of the E-cadherin and p120" immunoreactiv 
ity at the cell-cell junction was either lost or redistributed to 
the cytoplasm (not shown). 
Forced 8-catenin overexpression in CWR-R1 derived from 
human prostate cancer Xenograft induces the reduction of 
E-cadherin and p120" at the cell-cell junction. Because 
6-catenin binds to the same JMD region on E-cadherin as 
p120", an increased 6-catenin expression may compete with 
p120" for E-cadherin binding. As shown above, increased 
Ö-catenin expression in prostatic adenocarcinomas indeed 
corresponded to the loss of E-cadherin and p120" at the 
cell-cell junction and their concomitant increases in cytoplas 
mic immunoreactivities (data not shown). To further examine 
the hypothesis that an increased 6-catenin expression can 
affect the E-cadherin and p120" at the cell-cell junction, we 
overexpressed 6-catenin ectopically into prostate epithelial 
cells in culture. 
CWR-R1 cells (Gregory et al., Cancer Res.61(7): 2892 
2898, 2001) were derived from a recurrent human prostate 
cancer xenograft (Pretlow et al., supra 1993: Wainstein, M.A. 
et al., Cancer Res. 54 (23): 6049-6052, 1994). These cells 
grow inclusters in culture and displayed an enhanced 6-cate 
nin immunoreactivity when compared with PZ-HPV-7, a 
non-tumorigenic human prostate epithelial cell line. The level 
of 6-catenin expression in CWR-R1 was moderate when 
compared with that in neurons (not shown). This moderate 
level of 6-catenin expression was also demonstrated in cul 
ture by immunofluorescent light microscopy. In the cell clus 
ters, 6-catenin was localized at the cell-cell junction (not 
shown). In the same cell clusters, E-cadherin immunostaining 
corresponded mainly to the cell-cell contact area (not shown) 
and at least partially co-localized with 8-catenin at the cell 
cell junction (not shown). When pEGFP-8-catenin was over 
expressed in CWR-R1 cells by transfection, its localization at 
the cell-cell junction was clearly demonstrated (not shown), 
along with some cytoplasmic immunoreactivity. Here, the 
purple line demarcated the untransfected cells in the field. 
When E-cadherin immunoreactivity was examined, the 
untransfected cells showed the same cell-cell junction stain 
ing. But the cells transfected with 8-catenin showed a reduced 
E-cadherin immunoreactivity (not shown). When the merged 
images were analyzed, no co-localization of E-cadherin and 
Ö-catenin at the cell-cell junction area could be demonstrated. 
We also examined the p120" immunoreactivity and dis 
tribution in the CWR-R1 cells transfected with pEGFP-6- 
catenin. Untransfected cells showed p120" localization at 
the cell-cell junction (data not shown). However, cells trans 
fected with 8-catenin showed the reduced p120" immunore 
activity (data not shown). In addition, p120" staining at the 
cell-cell junction was very weak, which was also shown by 
the lack of merged yellow staining at the cell-cell contact area 
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(data not shown). As an additional control. CWR-R1 cells 
were transfected with EGFP vector alone, which uniformly TABLE IV 
distributed in the cytoplasm (data not shown). The untrans 
fected cells were highlighted with the red lines (not shown). 
Here, anti-p120" immunoreactivity was localized to the 
cell-cell junction, whether in transfected or untransfected Cases of false negative by one biomarker Successful correction using 
cells (not shown). The merged images showed strong red immunoreactivity: 8-catenin. E-adherin?p120" 
signals in most of the cells (not shown). 
Probability of Successful prediction of prostate cancer using 8-catenin 
E-cadherin-p120" immunoscore as a biomarker cluster. 
6-catenin 5/6 (83%) 
10 (n = 6) 
TABLE I E-cadherin 24/39 (62%) 
(n = 39) 
Paired analysis of 8-catenin immunoscores in benign versus prostate p120etn 49/62 (79%) 
tumor sections. (n = 62) 
Immunoscore 15 The foregoing is illustrative of the present invention, and is 
C Beni C Beni C Beni not to be construed as limiting thereof. The invention is 8CE > sell.9 8CE = sell.9 8CE 3 still 9. 9. gil defined by the following claims with equivalents of the claims 
Number 55.65 6.65 4f6S to be included therein. 
of Cases (85%) (9%) (6%) 2O That which is claimed is: 
1. A method for detecting cancer in a subject comprising 
*Out of 90 cases, total 65 benign sections and 65 prostate tumor sections can the steps of: 
be used for direct, paired comparison obtaining a body fluid sample from said Subject, wherein 
said body fluid sample is a urine sample, and 
TABLE II 25 determining the presence of an increased level of delta 
catenin in said body fluid sample as compared to a nor 
Comparison of 8-catenin, E-cadherin and p120" immunoscores* in mal or control Sub ect, 
-predicting prostate cancer- the presence of an increased level of delta-catentin in said 
I body fluid sample indicating said subject has prostate 
OSCOe 
30 CaCC. 
Benign Cancer 2. The method of claim 1 wherein said subject is a human. 
3. The method of claim 1 wherein said determining step Markers Strong Moderate Weak Strong Moderate Weak comprises the steps of 
8-catenin 1065 6.65 49,6S 46,72 20,72 6,72 contacting said sample with anti-delta-catenin antibodies 
E g (5. 3. so 35 to form an anti-delta-catenin antigen complex; and 
cadherin (90%) (6%) (4%) (44%) (22%) (34%) detecting the presence of anti-delta-catenin antigen com 
p120etn 71/71 Of 71 Of 71 62.88 8,88. 18,88 plex: - 
(100%) (0%) ()%) (70%) (9%) (21%) wherein the presence of antigen-antibody complex indi 
cates the presence of cancer. 
*Total 65 benign cases and 72 prostatic adenocarcinoma specimens stained 4. The method of claim 1 wherein said determining step 
with anti-Ö-catenin, 71 benign cases and 89 prostatic adenocarcinoma speci- 40 
mens stained with anti-E-cadherin, and 71 benign cases and 88 prostatic comprises the steps of: 
adenocarcinoma samples stained with p120" can be used for direct com- contacting said sample with anti-delta-catenin antibodies 
parison to form an anti-delta-catenin antigen complex; and 
measuring the amount of anti-delta-catenin antigen com 
TABLE III 45 plex, - 0 
wherein elevated levels of antigen-antibody complex indi 
The comparison of the ability of 8-catenin, E-cadherin and p120" cates the presence of cancer, with greater levels of anti 
immunoscores in correcting each other's false negative outcomes in gen-antibody complex indicating greater severity O 
-predicting prostate cancer- progression of said cancer. 
6-catenin E-cadherin p120cm 5. A method of screening for cancerina subject comprising 
correction correction correction the steps of: 
C ffal tive b obtaining a body fluid sample from said subject, and 
8SCS O 8ISC (98.We 
one biomarker 9. y determining the presence of an increased level of delta 
immunoreactivity: catenin in said body fluid sample as compared to a nor 
mal or control Subject, 
8-catenin 6 46 56 the presence of an increased level of delta-catentin in said 
lein S. (7) body fluid sample indicating said subject is afflicted with 
(n = 39) (62%) (0%) (13%) Cancer, 
p120etn 31,62 29.62 Of 62 wherein said Subject is male, said cancer is prostate cancer, 
(n = 62) (50%) (47%) (0%) 60 and said body fluid sample is a urine sample. 
k k k k k 
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